The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Gustav Smith, MD, PhD

Gustav Smith

Associate professor

Gustav Smith, MD, PhD

Efficacy of the antibacterial envelope to prevent cardiac implantable electronic device infection in a high-risk population

Author

  • Uzma Chaudhry
  • Rasmus Borgquist
  • J Gustav Smith
  • David Mörtsell

Summary, in English

Aims

Infection is a serious complication of cardiac implantable electronic device (CIED) therapy. An antibiotic-eluting absorbable envelope has been developed to reduce the infection rate, but studies investigating the efficacy and a reasonable number needed to treat in high-risk populations for infections are limited.
Methods and results

One hundred and forty-four patients undergoing CIED implantation who received the antibacterial envelope were compared with a matched cohort of 382 CIED patients from our institution. The primary outcome was the occurrence of local infection, and secondary outcomes were any CIED-related local or systemic infections, including endocarditis, and all-cause mortality. The results were stratified by a risk score for CIED infection, PADIT. The envelope group had a higher PADIT score, 5.9 ± 3.1 vs. 3.9 ± 3.0 (P < 0.0001). For the primary endpoint, no local infections occurred in the envelope group, compared with 2.6% in the control group (P = 0.04), with a more pronounced difference in the stratum with a high (>7 points) PADIT score, 0 vs. 9.9% (P = 0.01). The total CIED-related infections were similar between groups, 6.3% compared with 5.0% (P = 0.567). Mortality after 1600 days of follow-up did not differ between groups, 22.9 vs. 26.4%, P = 0.475.
Conclusion

Our study confirms the clinical efficacy of an antibacterial envelope in the prevention of local CIED infection in patients with a higher risk according to the PADIT score. In an effort to improve cost–benefit ratios, ration of use guided by the PADIT score is advocated. Further prospective randomized studies in high-risk populations are called for.

Department/s

  • Cardiology
  • Department of Clinical Sciences, Lund
  • WCMM-Wallenberg Centre for Molecular Medicine
  • EXODIAB: Excellence of Diabetes Research in Sweden

Publishing year

2022-08-22

Language

English

Pages

1973-1980

Publication/Series

Europace

Volume

24

Issue

12

Document type

Journal article

Publisher

Oxford University Press

Topic

  • Cardiac and Cardiovascular Systems
  • Health Care Service and Management, Health Policy and Services and Health Economy

Keywords

  • Cardiac implantable electronic device
  • Infection
  • An antibiotic-eluting absorbable envelope
  • TYRX
  • Health economy

Status

Published

Project

  • TYRX i en högrisk population

ISBN/ISSN/Other

  • ISSN: 1532-2092